HKUMed reveals that Resmetirom, a drug for treating metabolic dysfunction-associated fatty liver disease (MAFLD), has the potential to prevent and suppress liver cancer caused by fatty liver disease. The research is led by Professor Irene Ng Oi-lin (middl (IMAGE)

The University of Hong Kong

HKUMed reveals that Resmetirom, a drug for treating metabolic dysfunction-associated fatty liver disease (MAFLD), has the potential to prevent and suppress liver cancer caused by fatty liver disease. The research is led by Professor Irene Ng Oi-lin (middl

Caption

HKUMed reveals that Resmetirom, a drug for treating metabolic dysfunction-associated fatty liver disease (MAFLD), has the potential to prevent and suppress liver cancer caused by fatty liver disease. The research is led by Professor Irene Ng Oi-lin (middle, front row).

Credit

HKU

Usage Restrictions

Media

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.